NCT03401073View on ClinicalTrials.gov

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

February 1, 2022

Study Completion Date

February 1, 2022

Conditions
Small Fiber NeuropathyIdiopathic Peripheral Neuropathy
Interventions
DRUG

Intravenous immunoglobulin

Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.

DRUG

0.9% Sodium Chloride

Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.

Trial Locations (1)

02215

Beth Israel Deaconness Medical Center, Boston

All Listed Sponsors
collaborator

Phoenix Neurological Associates, LTD

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT03401073 - IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3 | Biotech Hunter | Biotech Hunter